Metastatic breast cancer
Conditions
Interventions
Patients of administerd taxane after eribulin in 1st or 2nd line chemotherapy for metastatic breast cancer.
Sponsors
Yamaguchi University Graduate School of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)metastatic breast cancer(HER2-) 2)ECOG performance status 0-1 3)The presence of at least one measurable lesion 4)The patients with the measurable lesion by RECIST1.1 5)The patients of eribulin followed by taxane 6)The patients with adequate organ function neutrophil count>1000 Platelet count>75,000 Hemoglobin>9.0 AST/ALT<=75 Total bilirubin<1.5 Serum creatinine<1.5 7)Age>=20years,<80years 8)Written informed concent
Exclusion criteria
Exclusion criteria: 1)HER2+ 2)Concurrent active infections 3)The presence of brain metastasis requiring treatment 4)Sever complications Current uncontorolled CHF History of myocardial infractionwithin 6 months of randomization Cirrhosis of the liver Interstitial pneumonaitis Hemorrhagic Diathesis 5)Patients with synchronous double cancer 6)Pregnant or nursing women or who suspected pregnant 7)The patients combination has been chemotherapy,immunotherapy,hormone therapy,radiation therapy and surgical treatment 8)Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TTP(Time to progression) of taxane after administration of eribulin. (Comparison of literature data) | — |
Countries
Japan
Contacts
Public ContactNoriko Maeda
Yamaguchi University Graduate School of Medicine Department of Gastroenterological, Breast and Endocrine Surgery
Outcome results
None listed